# OnCo record destiny-lung01 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/destiny-lung01/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "destiny-lung01", "NCT03505710" ;
  schema:name "DESTINY-Lung01"@en ;
  schema:description "DESTINY-Lung01 showed that the antibody-drug conjugate trastuzumab deruxtecan shrank tumours in more than half of people whose lung cancer carried a HER2 mutation, which led to the first approved HER2-targeted treatment for lung cancer."@en ;
  schema:url <https://onco.cc/trials/destiny-lung01/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03505710> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/her2-mutant-nsclc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:people <https://onco.cc/people/bob-li/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-destiny-lung01-nejm-2022/> .